Anika Therapeutics Q2 2024 Adj. EPS $0.17 Beats $0.05 Estimate, Sales $41.920M Miss $42.099M Estimate
Portfolio Pulse from Benzinga Newsdesk
Anika Therapeutics (NASDAQ:ANIK) reported Q2 2024 adjusted EPS of $0.17, beating the $0.05 estimate by 240%. However, sales of $41.920M missed the $42.099M estimate by 0.43%. EPS decreased by 45.16% YoY, and sales decreased by 5.38% YoY.
August 08, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anika Therapeutics reported Q2 2024 adjusted EPS of $0.17, significantly beating the $0.05 estimate. However, sales of $41.920M missed the $42.099M estimate. EPS decreased by 45.16% YoY, and sales decreased by 5.38% YoY.
The significant beat on EPS is a positive indicator and may boost investor confidence in the short term. However, the miss on sales and the YoY decreases in both EPS and sales could temper enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100